Cargando…
Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report
An 80-year-old male patient was diagnosed to have squamous cell carcinoma of the lung which had a high level of programmed death-ligand 1 (PD-L1) expression. He was prescribed with intravenously administered nivolumab combined with carboplatin and paclitaxel as the first-line therapy. A rapid remiss...
Autores principales: | Fan, Frank S, Yang, Chung-Fan, Chang, Chia-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6837275/ https://www.ncbi.nlm.nih.gov/pubmed/31772851 http://dx.doi.org/10.7759/cureus.5881 |
Ejemplares similares
-
Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma
por: Guan, Jian, et al.
Publicado: (2019) -
Soluble Programmed Death-Ligand 1 (sPD-L1) as a Promising Marker for Head and Neck Squamous Cell Carcinoma: Correlations With Clinical and Demographic Characteristics
por: Alrehaili, Amani A, et al.
Publicado: (2023) -
Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023) -
Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer
por: You, Maojin, et al.
Publicado: (2023) -
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
por: Mudad, Raja, et al.
Publicado: (2017)